Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIORA THERAPEUTICS, INC.PROG · Entity 85047 | Director | June 14, 2021 | June 16, 2021 |
| Coherus Oncology, Inc.CHRS · Entity 6276 | Director | January 11, 2021 | January 13, 2021 |
| Motus GI Holdings, Inc.MOTS · Entity 93100 | Director | February 17, 2021 | February 19, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIORA THERAPEUTICS, INC.
Report date June 14, 2021 · Filed June 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,518 |
Reported balance
After 2021-06-14 transaction · row 1
1 source rowRow 1 · 2021-06-14 · Grant · Acquired 29,183 · Balance 47,518 F1: Represents 29,183 restricted stock units, which vest in full on the earlier of (1) June 14, 2022 or (2) the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.17 · Expires 2031-06-14 | Direct | 51,724 |
Reported balance
After 2021-06-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-06-14 · Grant · Acquired 51,724 · Balance 51,724 F2: This option represents the right to purchase 51,724 shares of the Issuer's common stock, which vest in full on the earlier of (1) June 14, 2022 or (2) the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 29,183 restricted stock units, which vest in full on the earlier of (1) June 14, 2022 or (2) the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.
F2: This option represents the right to purchase 51,724 shares of the Issuer's common stock, which vest in full on the earlier of (1) June 14, 2022 or (2) the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.
Coherus Oncology, Inc.
Report date January 11, 2021 · Filed January 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.58 · Expires 2031-01-11 | Direct | 20,000 |
Reported balance
After 2021-01-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-11 · Grant · Acquired 20,000 · Balance 20,000 F1: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Motus GI Holdings, Inc.
Report date February 17, 2021 · Filed February 19, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 97,689 |
Ending reported balance
After 2021-02-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-02-17 · Grant · Acquired 30,000 · Balance 77,464 F1: On February 17, 2021, Reporting Person was granted 30,000 Common Stock restricted stock units. The restricted stock units vest as to 100% of the shares on February 17, 2022. Each restricted stock unit represents a contingent right to receive one share of Common Stock. The restricted stock units award was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan"). Row 2 · 2021-02-17 · Grant · Acquired 20,225 · Balance 97,689 F2: On February 17, 2021, Reporting Person was granted 20,225 shares of Common Stock as compensation in lieu of cash for Reporting Persons service as a director for calendar year 2021, pursuant to the Company's non-employee director compensation policy. The grant was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.78 · Expires 2031-02-17 | Direct | 30,000 |
Reported balance
After 2021-02-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-02-17 · Grant · Acquired 30,000 · Balance 30,000 F3: The option award was made in accordance with the terms of the 2016 Plan. The option becomes exercisable as to 100% of the shares on February 17, 2022. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2016 Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 17, 2021, Reporting Person was granted 30,000 Common Stock restricted stock units. The restricted stock units vest as to 100% of the shares on February 17, 2022. Each restricted stock unit represents a contingent right to receive one share of Common Stock. The restricted stock units award was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan").
F2: On February 17, 2021, Reporting Person was granted 20,225 shares of Common Stock as compensation in lieu of cash for Reporting Persons service as a director for calendar year 2021, pursuant to the Company's non-employee director compensation policy. The grant was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan").
F3: The option award was made in accordance with the terms of the 2016 Plan. The option becomes exercisable as to 100% of the shares on February 17, 2022. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2016 Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2021 Filed Jun 16, 2021 18:06 UTC | BIORA THERAPEUTICS, INC. PROG · Entity 85047 | GrantStock Option (Right to Buy) · Derivative | 51,724 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0000899243-21-024208 · doc4.xml · derivative · entry 2 NUSSBAUM SAMUEL R MD · CIK 0001199310 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,724 Underlying: Common Stock · 51,724 shares Expires 2031-06-14 F2 · deemedExecutionDate: This option represents the right to purchase 51,724 shares of the Issuer's common stock, which vest in full on the earlier of (1) June 14, 2022 or (2) the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. F2 · derivative.exercise_date: This option represents the right to purchase 51,724 shares of the Issuer's common stock, which vest in full on the earlier of (1) June 14, 2022 or (2) the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 18:06 UTC | BIORA THERAPEUTICS, INC. PROG · Entity 85047 | GrantCommon Stock | 29,183 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-024208 · doc4.xml · nonDerivative · entry 1 NUSSBAUM SAMUEL R MD · CIK 0001199310 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,518 F1 · shares: Represents 29,183 restricted stock units, which vest in full on the earlier of (1) June 14, 2022 or (2) the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 16:16 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001213900-21-010580 · ownership.xml · derivative · entry 3 NUSSBAUM SAMUEL R MD · CIK 0001199310 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock, par value $0.0001 per share · 30,000 shares Expires 2031-02-17 F3 · derivative.exercise_date: The option award was made in accordance with the terms of the 2016 Plan. The option becomes exercisable as to 100% of the shares on February 17, 2022. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2016 Plan. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 16:16 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | GrantCommon Stock, par value $0.0001 per share | 20,225 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-010580 · ownership.xml · nonDerivative · entry 2 NUSSBAUM SAMUEL R MD · CIK 0001199310 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,689 F2 · shares: On February 17, 2021, Reporting Person was granted 20,225 shares of Common Stock as compensation in lieu of cash for Reporting Persons service as a director for calendar year 2021, pursuant to the Company's non-employee director compensation policy. The grant was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan"). Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 16:16 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | GrantCommon Stock, par value $0.0001 per share | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-010580 · ownership.xml · nonDerivative · entry 1 NUSSBAUM SAMUEL R MD · CIK 0001199310 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,464 F1 · shares: On February 17, 2021, Reporting Person was granted 30,000 Common Stock restricted stock units. The restricted stock units vest as to 100% of the shares on February 17, 2022. Each restricted stock unit represents a contingent right to receive one share of Common Stock. The restricted stock units award was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan"). Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 09:04 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | GrantCommon Stock, par value $0.0001 per share | 8,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-002118 · ownership.xml · nonDerivative · entry 1 NUSSBAUM SAMUEL R MD · CIK 0001199310 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,464 F1 · shares: On January 12, 2021, Reporting Person was granted 8,334 shares of Common Stock as compensation for Reporting Persons service as a director during the fourth quarter of 2020, pursuant to the Company's non-employee director compensation policy. The grant was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan"). Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 16:26 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $17.58 | $0.00 |
DisclosureSEC source: 0001567619-21-000985 · doc1.xml · derivative · entry 1 NUSSBAUM SAMUEL R MD · CIK 0001199310 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-01-11 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| October 12, 2020 Filed Oct 13, 2020 17:02 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | GrantCommon Stock, par value $0.0001 per share | 9,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-031107 · ownership.xml · nonDerivative · entry 1 NUSSBAUM SAMUEL R MD · CIK 0001199310 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,130 F1 · shares: On October 12, 2020, Reporting Person was granted 9,430 shares of Common Stock as compensation for Reporting Persons service as a director during the third quarter of 2020, pursuant to the Company's non-employee director compensation policy. The grant was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan"). Read SEC document |
| July 10, 2020 Filed Jul 13, 2020 16:15 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | GrantCommon Stock, par value $0.0001 per share | 7,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-017336 · ownership.xml · nonDerivative · entry 1 NUSSBAUM SAMUEL R MD · CIK 0001199310 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,700 F1 · shares: On July 10, 2020, Reporting Person was granted 7,200 shares of Common Stock as compensation for Reporting Persons service as a director during the second quarter of 2020, pursuant to the Company's non-employee director compensation policy. The grant was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan"). Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 16:36 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001213900-20-002931 · ownership.xml · derivative · entry 2 NUSSBAUM SAMUEL R MD · CIK 0001199310 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock, par value $0.0001 per share · 12,500 shares Expires 2030-02-06 F2 · derivative.exercise_date: The option award was made in accordance with the terms of the 2016 Plan. The option becomes exercisable as to 50% of the shares on February 6, 2021, and the remaining shares will become exercisable on February 6, 2022. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2016 Plan. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 16:36 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | GrantCommon Stock, par value $0.0001 per share | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-002931 · ownership.xml · nonDerivative · entry 1 NUSSBAUM SAMUEL R MD · CIK 0001199310 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 F1 · shares: On February 6, 2020, Reporting Person was granted 12,500 Common Stock restricted stock units. The restricted stock units vest as to 50% of the shares on February 6, 2021, and the remaining restricted stock unit shares vest on February 6, 2022. Each restricted stock unit represents a contingent right to receive one share of Common Stock. The restricted stock units award was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan"). Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 17:51 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $17.73 | $0.00 |
DisclosureSEC source: 0001567619-20-001042 · doc1.xml · derivative · entry 1 NUSSBAUM SAMUEL R MD · CIK 0001199310 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-01-10 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2020, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| February 13, 2019 Filed Feb 15, 2019 17:01 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001615774-19-002641 · s116119_form4.xml · derivative · entry 1 NUSSBAUM SAMUEL R MD · CIK 0001199310 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock, par value $0.0001 per share · 25,000 shares Expires 2029-02-13 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan"). The option becomes exercisable as to 50% of the shares on February 13, 2020, and the remaining shares will become exercisable on February 13, 2021. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2016 Plan. Read SEC document |
| January 11, 2019 Filed Jan 30, 2019 16:07 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $12.37 | $0.00 |
DisclosureSEC source: 0000899243-19-002191 · doc4.xml · derivative · entry 1 NUSSBAUM SAMUEL R MD · CIK 0001199310 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-01-11 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 11, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| May 09, 2018 Filed May 11, 2018 16:07 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $15.60 | $0.00 |
DisclosureSEC source: 0000899243-18-012528 · doc4.xml · derivative · entry 1 NUSSBAUM SAMUEL R MD · CIK 0001199310 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-05-09 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/36th of the total number of shares subject to the option in successive, equal monthly installments measured from May 9, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 06:05 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | PurchaseCommon Stock, par value $0.0001 per share | 10,000 | $5.00 | $50,000.00 |
DisclosureSEC source: 0001493152-18-002418 · form4.xml · nonDerivative · entry 1 NUSSBAUM SAMUEL R MD · CIK 0001199310 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · kind: The securities were purchased pursuant to an underwritten public offering by the Issuer. The offering closed on February 16, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.